Company Overview

Elite Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on the development, manufacture, and commercialization of generic pharmaceutical products, with a primary emphasis on controlled-release and abuse-deterrent drug technologies. The company operates within the pharmaceutical and drug manufacturing industries and derives revenue primarily from the sale of generic prescription products, manufacturing and licensing agreements, and product development collaborations. Its portfolio has historically included products in therapeutic categories such as central nervous system disorders, pain management, and cardiovascular treatments.

The company’s business model combines in-house research and development with commercial manufacturing capabilities. Elite has positioned itself around niche generic products and proprietary delivery technologies designed to improve dosing control and support abuse-deterrent formulations. Founded in 1997 and headquartered in Northvale, New Jersey, the company evolved from a development-stage pharmaceutical enterprise into a commercial-stage generic drug manufacturer with FDA-approved products and manufacturing operations in the United States.

Business Operations

Elite Pharmaceuticals conducts operations primarily through its pharmaceutical development and manufacturing activities in the United States. The company develops abbreviated new drug applications (ANDAs) and manufactures oral solid-dose pharmaceuticals, including immediate-release and controlled-release formulations. Revenue is generated through product sales, contract manufacturing, licensing arrangements, and partnerships with pharmaceutical distributors and marketing organizations. The company’s operational infrastructure includes formulation development, analytical testing, regulatory support, and commercial-scale manufacturing capabilities.

Key operational assets include its proprietary controlled-release and abuse-deterrent technology platforms, as well as FDA-inspected manufacturing facilities. Elite has historically collaborated with commercial partners for product distribution and market access while retaining portions of manufacturing and development activities internally. The company has also operated through subsidiaries including Elite Laboratories, Inc., which supports manufacturing and product development activities. Public disclosures indicate ongoing investment in expanding product pipelines and manufacturing utilization.

Strategic Position & Investments

Elite Pharmaceuticals has focused its strategic direction on expanding its portfolio of generic pharmaceuticals while leveraging proprietary drug delivery technologies to differentiate products in competitive markets. Growth initiatives have included filing additional ANDAs, pursuing niche generic opportunities with limited competition, and expanding commercial manufacturing capacity. The company has also emphasized abuse-deterrent opioid technologies and extended-release formulations as areas of long-term strategic relevance within the pharmaceutical sector.

The company has pursued selective licensing arrangements and product development partnerships to support commercialization and broaden market reach. Strategic investments have centered on manufacturing infrastructure, regulatory compliance, and product pipeline expansion rather than large-scale acquisitions. Elite’s positioning in specialized oral dosage technologies has been presented as a competitive advantage in targeting complex generic formulations. Public filings and company disclosures support ongoing efforts to increase the number of marketed products and diversify revenue streams.

Geographic Footprint

Elite Pharmaceuticals’ primary operational footprint is concentrated in the United States, where the company maintains its headquarters and principal manufacturing operations in New Jersey. Its commercial activities are largely tied to the U.S. generic pharmaceutical market, including distribution through domestic pharmaceutical wholesalers, distributors, and commercial partners. FDA regulatory oversight plays a central role in the company’s operational and market activities.

While the company’s direct international operational presence appears limited based on publicly available disclosures, its products and supply chain relationships may involve international sourcing and pharmaceutical industry partners. Data regarding extensive overseas subsidiaries or material foreign operating segments is inconclusive based on available public sources. The company’s strategic emphasis remains primarily focused on the U.S. prescription generic drug market.

Leadership & Governance

Elite Pharmaceuticals is led by a management team with experience in pharmaceutical development, manufacturing, regulatory compliance, and commercialization. The company’s governance structure includes executive leadership and a board of directors overseeing strategic direction, operational execution, and regulatory responsibilities. Leadership communications and public filings have emphasized product pipeline growth, operational efficiency, and long-term shareholder value creation through expansion of marketed generic products and proprietary technologies.

Key executives include:

• Nasrat Hakim – Chairman and Chief Executive Officer
• Carter Ward – Chief Financial Officer
• Vivek Jayant Venkat – President and Chief Operating Officer

The company’s leadership strategy has centered on disciplined product development, regulatory execution, and leveraging internal manufacturing capabilities to support scalable commercial growth within the generic pharmaceutical sector.